Kimberly is the Chief Executive Officer at Zentalis Pharmaceuticals. Prior to joining Zentalis, she served as Chief Medical Officer and Senior Vice President, Oncology Clinical Development, at Tempus Labs. In this role, she oversaw precision medicine initiatives to improve cancer care and guide therapeutic drug development and discovery. Prior to joining Tempus, Kim was VP of Early Phase Oncology and Immunology-oncology at Eli Lilly and Company, where she worked on early stage cancer therapeutics. During her time at Lilly, she was named as one of “Twenty extraordinary women in biopharma R&D who worked their way to the top” by Endpoints News. For 18 years, Kim was a faculty member at the Duke University Cancer Institute. While at Duke, she served as the principal or co-principal investigator for over 50 cancer clinical trials, co-founded the radiotherapeutics company-Cereius, and co-directed the Woman’s Cancer Program and Precision Medicine Initiative. As one of the nation’s leading breast cancer researchers, she played a role in developing therapies that represent revolutionary non-chemotherapy-based approaches for treating cancer. This work led to Kim’s  inclusion in TIME Magazine’s 100 Most Influential People in the World for 2013, recognizing her accomplishments contributing to the development of lapatinib and T-DM1 for the treatment of HER2+ breast cancer. She holds a BA degree in Bioethics from Duke University and a MD degree from Mayo Clinic Medical School.

Cam is a cofounder and President at Zentalis Pharmaceuticals and has served as a member of the Board of Directors since the Company’s founding. He has 30 years of experience in the life sciences, with a focus on corporate development, marketing and company formation, and financing. In addition to Zentalis, Cam currently serves on the Board of Directors of Ocuphire, Helios, SelectION and Ray Therapeutics. He was also a founding Board member of VelosBio until its acquisition by Merck. From April 2016 to May 2022, he was the Chief Business Officer of Immusoft, a private company developing gene modified cell therapies for orphan diseases. Previously, Cam was a board member and Chief Business Officer at Retrosense Therapeutics, which was acquired by Allergan. He was also the Managing Director of Nerveda, LLC, a life science seed fund he co-founded in June 2007. Prior to these roles, he held leadership positions at Oncternal, Zavante, Verus Pharma, CV Therapeutics and Dura Pharma. Cam holds an MBA from the University of San Diego and a BS in Business Administration from Ohio University.

Interesting Fact: Cam attended the coldest game in NFL history, the Freezer Bowl (-59 degrees wind chill).

Kevin is a co-founder and Chief Operating Officer at Zentalis Pharmaceuticals. He leads our R&D team in San Diego. Prior to joining Zentalis, Kevin was a co-founder of Kalyra Pharmaceuticals and currently serves on the board of directors of Kalyra and as its Chief Scientific/Operations Officer. Prior, he was in Pfizer’s drug discovery research group in La Jolla as part of the Medicinal Chemistry Department. He specialized in multiple therapeutic areas including Oncology, Diabetes, Antivirals, and Ophthalmology. Prior to Pfizer, Kevin carried out postdoctoral research at The Scripps Research Institute under the direction of Professor Dale Boger. He received his PhD in Organic Chemistry from the University of California, San Diego under the direction of Joseph O’Connor and his BS in Chemistry from Arizona State University. Kevin is the inventor on multiple patents and an author of multiple articles in peer-reviewed journals.

Interesting Fact: Kevin sold precious metals from his late grandfather (Dr. Duane Brown) that were refined from eyeglass frames, circuit boards, and dental scraps to help kick-off Kalyra.

Melissa is Chief Financial Officer at Zentalis Pharmaceuticals. She brings extensive experience as a senior financial executive in the life sciences industry. She most recently served as CFO at PsiOxus Therapeutics, a clinical-stage gene therapy cancer company, and prior to that, CFO and Head of Business Development at R-Pharm US, a commercial-stage oncology company. Previously, Melissa was a Director at Anchorage Capital Group, a credit-focused hedge fund; a Vice President at Goldman Sachs in equity research in New York and London where she built GS SUSTAIN; and a management consultant with Bain & Company focused on international and US based pharmaceutical clients and private equity. She began her career at Morgan Stanley in New York in healthcare investment banking. Melissa earned her MBA from Harvard Business School and BA in Biochemistry and Economics from the University of Virginia, where she graduated Phi Beta Kappa.

Interesting Fact: Melissa logged six hours towards her pilot’s license and twice attended NASA’s Space Camp before the age of 12.

Andrea Paul joined Zentalis in August 2022 as General Counsel and Corporate Secretary. Previously, Ms. Paul served as General Counsel and Corporate Secretary of LogicBio Therapeutics, Inc., where she led the company’s legal team and served as a key strategic legal partner in the company’s finance, business development and contractual decision-making matters. Before that, she held positions of increasing responsibility at Akebia Therapeutics, Inc., culminating in the role of Vice President, Legal. While at Akebia, Ms. Paul was a key strategic legal partner in the company’s merger with Keryx Biopharmaceuticals, Inc. as well as in the company’s financing and business development transactions. Prior to Akebia, she served as Senior Corporate Counsel at Momenta Pharmaceuticals, Inc. She began her legal career working as an associate at Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. and Sullivan and Cromwell LLP. Ms. Paul currently chairs the Securities Law Committee of the Boston Bar Association. She received her J.D. from Harvard Law School and her B.A. in Art History from Columbia University.

Interesting Fact: Andrea is a dedicated Michael Schumacher fan and still watches replays of his F1 races.

As Senior Vice President of Discovery Research at Zentalis Pharmaceuticals, Peter has led multiple programs from early discovery into the clinic and heads many key functions, such as overseeing Internal/External Discovery, Process Chemistry, intellectual property, and external collaborations. Previously, he worked at Pfizer as one of their lead oncology chemistry designers and focused on the discovery of small molecule drugs. Dr. Huang has published over 50 peer-reviewed papers and patents and was the key inventor of six clinical compounds including the 2nd generation ALK inhibitor lorlatinib approved in 2018. Dr. Huang received his BS in Chemistry from Nankai University, PhD in Organic Chemistry from Iowa State University and completed his postdoc training at University of Chicago. He is also the President of SABPA, a 501(c)3 nonprofit organization with the mission of promoting science and innovation.

Interesting Fact: While driving a small fishing board at high speed, Peter once charmed a pod of dolphins into accompanying him.

Meena brings more than 20 years of global pharmaceutical development experience and serves as Zentalis Pharmaceuticals’ Vice President for Regulatory Affairs and Quality Assurance. Prior to Zentalis, Dr. Rao held various positions at IQVIA, Novo Nordisk and Bristol Myers Squibb, the more recent being Senior Director and Head of Regulatory Strategy at IQVIA, Singapore. Her regulatory affairs expertise spans global disciplines of clinical, non-clinical, CMC, advertising, promotion, and pre/post-marketing across multiple therapeutic areas including Oncology, Diabetes, Obesity, Infectious Diseases, Inflammation, Hemostasis and Women’s Health. Dr. Rao was decorated with three of the highest-ranking awards for her work on Metaglip, Abatacept and Carboplatin at Bristol-Myers Squibb and the President’s Award for approval of Vagifem at Novo Nordisk. A chemist by training, Dr. Rao holds a PhD in Chemistry from the University of Louisville, MS/BS in Chemistry from the University of Lagos, and a BS in Chemistry from the University of Madras.

Interesting Fact: Meena has lived, worked and studied in three continents, from high school in Dar-es-salaam, Tanzania to earning her Bachelor’s in Madras, India and her PhD in the US.

Bob is Vice President of Manufacturing and Supply and Head of CMC at Zentalis Pharmaceuticals. He brings over 30 years of international pharmaceutical and biopharmaceutical experience in the design, implementation and operation of global supply chains for both commercial and investigational products. Prior to joining Zentalis, Bob served as Senior Vice President, Manufacturing and Supply for Zavante Therapeutics (acquired by Nabrivia Therapeutics in 2018), a late clinical-stage pharmaceutical company focused on developing novel therapies to improve the outcomes of hospitalized patients. Previously, Bob served as Vice President, Manufacturing and Supply for Cadence Pharmaceuticals. During his five year tenure, he developed and implemented the outsourced supply strategy for OFIRMEV^® (acetaminophen), a therapeutic used to treat pain and reduce fever, focusing on supply, security and speed to market. Prior to Cadence, Bob was Vice President, European Supply at Valeant Pharmaceuticals in Basel, Switzerland, where he oversaw the global manufacturing and supply responsibilities at the Company’s two major manufacturing sites. Over the course of his career, he has held several senior operations and engineering roles, in particular at GlaxoSmithKline in the US and UK. Bob received his MSc in Manufacturing from the University of Cambridge, England and BS in Environmental Engineering from Temple University. He is a registered Professional Engineer (P.E.) and is a contributing member of the International Society of Pharmaceutical Engineers (ISPE).

Interesting Fact: No matter where in the world Bob lived at the time, he made sure that he attended his annual golf reunion with his 16 best friends. This event went on for 25 years until it was retired in 2010.

Mr. Dave Johnson has more than 25 years of experience in the biopharmaceutical industry. Most recently, he was chairman of the preclinical precision oncology-focused company, Lengo Therapeutics, which was acquired by Blueprint Medicines in December 2021 in a transaction valued at up to $465M. Prior to Lengo, Dave was CEO of VelosBio an oncology-focused biopharmaceutical company that he founded in December 2017. VelosBio created novel monoclonal antibody-based therapeutics, rapidly moving its lead ROR1-directed antibody-drug-conjugate zilovertamab vedotin from pre-IND through Phase 1 clinical validation leading to the company’s acquisition by Merck in December 2020 for $2.75B. Before Velos, Mr. Johnson was with Acerta Pharma, an oncology-focused pharmaceutical company focused on covalent small-molecule technology, where he rose to CEO. At Acerta, he built out all facets of the corporation to accelerate the development of Bruton tyrosine kinase inhibitor, acalabrutinib (Calquence™), rapidly moving from early- to late-stage clinical development and launching four global registration-directed trials, including the accelerated approval study that led to acalabrutinib’s first regulatory approval. Dave’s tenure at Acerta culminated in the execution of a strategic transaction with AstraZeneca valued at $7B.

Kimberly is the Chief Executive Officer at Zentalis Pharmaceuticals. Prior to joining Zentalis, she served as Chief Medical Officer and Senior Vice President, Oncology Clinical Development, at Tempus Labs. In this role, she oversaw precision medicine initiatives to improve cancer care and guide therapeutic drug development and discovery. Prior to joining Tempus, Kim was VP of Early Phase Oncology and Immunology-oncology at Eli Lilly and Company, where she worked on early stage cancer therapeutics. During her time at Lilly, she was named as one of “Twenty extraordinary women in biopharma R&D who worked their way to the top” by Endpoints News. For 18 years, Kim was a faculty member at the Duke University Cancer Institute. While at Duke, she served as the principal or co-principal investigator for over 50 cancer clinical trials, co-founded the radiotherapeutics company-Cereius, and co-directed the Woman’s Cancer Program and Precision Medicine Initiative. As one of the nation’s leading breast cancer researchers, she played a role in developing therapies that represent revolutionary non-chemotherapy-based approaches for treating cancer. This work led to Kim’s  inclusion in TIME Magazine’s 100 Most Influential People in the World for 2013, recognizing her accomplishments contributing to the development of lapatinib and T-DM1 for the treatment of HER2+ breast cancer. She holds a BA degree in Bioethics from Duke University and a MD degree from Mayo Clinic Medical School.

Cam is a cofounder and President at Zentalis Pharmaceuticals and has served as a member of the Board of Directors since the Company’s founding. He has 30 years of experience in the life sciences, with a focus on corporate development, marketing and company formation, and financing. In addition to Zentalis, Cam currently serves on the Board of Directors of Ocuphire, Helios, SelectION and Ray Therapeutics. He was also a founding Board member of VelosBio until its acquisition by Merck. From April 2016 to May 2022, he was the Chief Business Officer of Immusoft, a private company developing gene modified cell therapies for orphan diseases. Previously, Cam was a board member and Chief Business Officer at Retrosense Therapeutics, which was acquired by Allergan. He was also the Managing Director of Nerveda, LLC, a life science seed fund he co-founded in June 2007. Prior to these roles, he held leadership positions at Oncternal, Zavante, Verus Pharma, CV Therapeutics and Dura Pharma. Cam holds an MBA from the University of San Diego and a BS in Business Administration from Ohio University.

Interesting Fact: Cam attended the coldest game in NFL history, the Freezer Bowl (-59 degrees wind chill).

Dr. Enoch Kariuki is an accomplished finance executive with over a decade of experience in healthcare strategy, life sciences investment banking, venture capital and business development. He most recently served as the Chief Financial Officer of VelosBio (acquired by Merck for $2.75 billion) where he led all finance-related and investor relations functions. Prior to VelosBio, he served as Senior Vice President, Corporate Development at Synthorx, where he led the company’s $151 million IPO, managed relationships with bankers, sell-side equity analysts and investors, and headed the business development process that concluded with the sale of Synthorx to Sanofi for $2.5 billion. Before Synthorx, Dr. Kariuki was Vice President at H.I.G. Capital, a $40 billion private equity firm, where he invested in and served on the boards of multiple life sciences companies. His other previous roles include Senior Associate at Leerink Partners and Associate Director at UBS Investment Bank. At Leerink and UBS, Dr. Kariuki advised healthcare companies on equity capital financings, mergers and acquisitions, leveraged buyouts, and recapitalizations.

Dr. Kariuki completed a Post-Doctoral Fellowship in R&D Strategy and Analytics at Bristol Myers Squibb and was a Pharmacist at CVS Caremark. He holds an MBA from the Tuck School of Business at Dartmouth College and a PharmD from Texas Southern University.

Dr. Jan Skvarka is an accomplished life sciences executive with decades of operational, strategic and financial experience. Jan currently serves as the Executive Chairman of GentiBio, Inc. and DEM BioPharma, Inc. Previously, Jan was the President and Chief Executive Officer of Trillium Therapeutics, Inc. (Nasdaq: TRIL), a clinical-stage immuno-oncology company, where he led a highly successful, 360-degree business transformation that produced a leading CD47 drug candidate, and took the company from a $16 million market capitalization to a $2.3 billion acquisition by Pfizer Inc. in two years. Before Trillium, Jan served as the President and Chief Executive Officer of Tal Medical, a private clinical-stage neuromodulation company, and a leading partner in the healthcare practice of Bain & Company. Jan holds an M.B.A. from Harvard Business School and a Ph.D. in Economics from the University of Economics in Slovakia.

Karan Takhar is a Managing Director and the head of Life Sciences investing at Matrix Capital Management, an investment fund focused on technology and life sciences. Mr. Takhar received a Bachelor of Science in Economics and Mathematics from the Massachusetts Institute of Technology.

Dr. Stephen Ansell’s clinical practice interests focus on non-Hodgkin lymphoma, Hodgkin’s disease, and Waldenstrom’s macroglobulinemia. His research focuses on the biology of these diseases and on developing new therapies. Dr. Ansell is Chair of the Mayo Clinic Lymphoma Group as well as Chair of the Faculty Development and Recruitment for Hematology at Mayo. He received his medical degree at the University of Pretoria, South Africa and subsequently completed his PhD at the same institution. He trained in medical oncology before coming to the United States. Dr. Ansell then completed a residency in internal medicine and a fellowship in Hematology-Oncology at Mayo Clinic.

Dr. Andrew Badley is a Professor of Infectious Diseases, and Professor and Chair of the Department of Molecular Medicine at Mayo Clinic. Dr Badley’s research focuses on the regulation of cell death during disease, notably HIV infection, and creating novel means of impacting aberrant cell death.

He earned his MD degree in 1990 from Dalhousie University in Halifax, Nova Scotia, and completed residency in internal medicine at Mayo Clinic in Rochester, MN, and further training at Mayo Clinic as a clinician investigator trainee in the Division of Infectious Diseases. Dr. Badley joined the staff of Ottawa Hospital in Ottawa, Ontario, Canada, in 1997 as an assistant professor in the Division of Infectious Diseases. In 2002, Dr. Badley returned to Mayo Clinic in Rochester as a consultant in the Division of Infectious Diseases and he remains active in clinical practice, research, research administration and entrepreneurial activities.

Dr. Shaji Kumar’s research focuses on the development of novel drugs for the treatment of myeloma, and he has presented nationally and internationally. He is the principal investigator of several phase 1 and phase 2 clinical trials exploring new drugs and combinations for newly diagnosed and relapsed myeloma. His laboratory is focused on understanding the role of bone marrow microenvironment in the development and progression of myeloma.

Dr. Shaji Kumar received his medical degree from All India Institute of Medical Sciences in New Delhi, India. His postdoctoral training included a residency in internal medicine from the All India Institute of Medical Sciences, followed by a residency in internal medicine and a fellowship in hematology-oncology at the Mayo Graduate School of Medicine in Rochester, Minnesota. He is currently the Medical Director for the Cancer Center Clinical Research Office which oversees the development, activation, conduct, and monitoring of interventional trials across the three site Mayo Clinic Cancer Center.

Dr. Anthony Letai is Professor of Medicine at Harvard Medical School and Dana-Farber Cancer Institute. His research focuses on the mechanisms by which cancer cells evade death, and on the application of that knowledge to the selective killing of cancer cells. He joined the faculty of DFCI and Harvard Medical School in 2004. He received his MD and PhD from the University of Chicago. He completed his residency in internal medicine at Brigham and Women’s Hospital, and a fellowship in hematology and oncology at DFCI. He did his postdoctoral research training in the laboratory of Dr. Stanley Korsmeyer.

Dr. Ross Levine is the Director of the Memorial Sloan Kettering Center for Hematologic Malignancies, Laurence Joseph Dineen Chair in Leukemia Research, Member of the Human Oncology and Pathogenesis Program, and Attending Physician at Memorial Sloan Kettering Cancer Center. Dr. Levine’s pioneering research has illuminated the genetic basis of myeloid malignancies, including studies that delineated the role of the JAK-STAT pathway and other oncogenic drivers in the pathogenesis of myeloproliferative neoplasms (MPN) and acute myeloid leukemia (AML). His current efforts focus on the role of mutations in epigenetic modifiers in MPN and AML pathogenesis and therapeutic response, investigation of the role of different signaling pathways in hematopoietic transformation, and mechanisms of resistance to targeted therapies in MPN/AML. He received his MD degree from Johns Hopkins University and his BS from Harvard University.

Dr. Donald McDonnell is Professor and Chairman at the Department of Pharmacology and Cancer Biology at Duke University, Glaxo-Wellcome Professor of Molecular Cancer Biology in the School of Medicine. His research focuses on the development and application of mechanism-based approaches to identify novel therapeutics for use in the treatment and prevention of hormonally responsive cancers. Specifically, the pharmaceutical exploitation of the estrogen and androgen receptors as therapeutic targets in breast and prostate cancers and in defining how these receptors influence the pathogenesis of these diseases. From these studies have emerged several drugs that are at various stages of clinical development. He received his PhD from Baylor College of Medicine, and his BSc in Biochemistry at the National University of Ireland, Galway. He is a member of the National Academy of Medicine.

Dr. Adam Schayowitz is the Vice President and Group Lead for the Breast Cancer and Precision Therapeutics Franchise at Pfizer Oncology, responsible for the Global Development programs and Medicine Teams within this group. Prior to this role, Dr. Schayowitz was responsible for the Prostate Cancer Franchise at Pfizer. Before joining Pfizer, Dr. Schayowitz led the global development of niraparib (Zejula) across ovarian, breast, prostate and lung cancer at TESARO.

Dr. Schayowitz received his Ph.D. from the University of Maryland and MBA from Johns Hopkins. He also sits on the Scientific Advisory Board of Cardiff Oncology and the Board of Directors of Prostate Cancer Research.

Dr. Kwok-Kin Wong is a Director, Division of Hematology and Medical Oncology, Anne Murnick Cogan and David H. Cogan Professor of Oncology, Department of Medicine at Laura and Isaac Perlmutter Cancer Center, NYU Langone Health. Dr. Wong obtained his MD, PhD degree at the Columbia University College of Physicians and Surgeons. He was trained in internal medicine at the Massachusetts General Hospital, and hematology and oncology at the Dana-Farber Cancer Institute, both at Harvard Medical School. He was previously the Scientific Director of the Belfer Institute for Applied Cancer Science at Dana-Farber Cancer Institute (DFCI)/ Harvard Medical School. He has authored more than 250 papers and has various patents on the molecular biology of cancer and aging. He is a member of the American Society of Clinical Investigation Association of American Physicians, the nation’s oldest honor society for physician-scientists. He also co-founded G1 Therapeutics.

Dr. Robert Glassman returned to OrbiMed Advisors in January 2021 as the only venture partner in public equity. Previously, he had been a private equity partner at OrbiMed from 2009-2010.

Dr. Glassman is a seasoned investment banker who most recently served as Vice Chairman at Credit Suisse. Prior to joining Credit Suisse, he spent a decade working at Bank of America Merrill Lynch in their investment banking group, most recently as a Managing Director focused on the life sciences. Earlier in his career, Dr. Glassman was with Merrill Lynch Global Private Equity where he oversaw a very successful healthcare portfolio and at McKinsey & Co where he consulted for a wide range of clients within their Pharmaceutical and Medical Products practice.

Dr. Glassman was a board-certified hematologist-oncologist who remains on the faculty of Weill Cornell as a Clinical Assistant Professor of Medicine. He has co-authored numerous articles in peer reviewed journals and spoken widely in industry and academic forums on clinical development, reimbursement, and data interpretation. Dr. Glassman received his AB magna cum laude from Harvard College and an MD from Harvard Medical School. He completed his residency in internal medicine at the Hospital of the University of Pennsylvania, and his fellowship in hematology and oncology at Weill Cornell. He also spent several years as a basic science investigator at Rockefeller University in the laboratory of Hidesaburo Hanafusa where he received Howard Hughes Medical Institute and American Cancer Society awards.

Chad Robins is the co-founder and CEO of Adaptive Biotechnologies, a commercial-stage biotech company that aims to translate the genetics of the adaptive immune system into diagnostics and therapeutics to improve patients’ lives. Prior to co-founding Adaptive, Chad held numerous executive-level positions in medical technology, investment and real estate companies. Chad holds an MBA from The Wharton School at the University of Pennsylvania and a BS in Managerial Economics from Cornell University.